appropriate by Dhipaya Bodin as a joint venture. It will benefit potential shareholders in the medical device and distribution business. The current production and distribution line is Blood Line with a

year. This was due to the higher earnings before tax. Please be informed accordingly. Sincerely yours, (Ms. Wannee Juntamongkol) Senior Vice President – Accounting and Finance

change in status to that of a subsidiary. This resulted in basic earnings per share of Bt0.88 for the first quarter of 2018. Total Asset Total assets as of March 31, 2018 amounted to Bt18,037 million

approved the Company’s Interim Financial Information ending March 31, 2018. The Company would like to clarify the three-month period ended March 31, 2018 earnings results, as follows. Statement of

dated February 23, 2019 approved the Company’s Financial Statement ending December 31, 2018. The Company would like to clarify the year ended December 31, 2018 earnings results, as follows. Statement of

reported net profit of Baht 24.8 million. Earnings per share was Baht 1.16. Nine-Month Period The Company reported consolidated revenues of Baht 1,296.0 million, decreased by 8.4%. Sales revenues reported

%) (31.79%) Tax income (expense) (2.64 ) 0.00 2.64 N/A (3.91%) 0.00% Profit (loss) for the period (23.21 ) (28.30 ) 5.09 17.99% (34.40%) (50.12%) Basic earnings per share-Owners of the Company (0.03 ) (0.03

Baht 971 million and earnings per share of Baht 0.49 a decrease of 10% when compared to the previous year. The Company would like to clarify the reasons for the change in profits for 2019 compared to the

/2020 dated February 22, 2020 approved the Company’s Financial Statement ending December 31, 2019. The Company would like to clarify the year ended December 31, 2019 earnings results, as follows

equity holders improved significantly compared to last year, attributable to increased earnings, higher share of profit from associate companies, and lower financing costs. In Q1 2017, the Company had